Surgery for colorectal peritoneal carcinomatosis

Scandinavian Journal of Gastroenterology

Volumn 47, Issue 3, 2012, Pages 277-285

  Chua, Terence C ^a,b   Pelz, Joerg O W ^c   Morris, David L ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

carcinomatosis; colorectal cancer; cytoreductive surgery; hyperthermic

Indexed keywords

ANTINEOPLASTIC AGENT; FLUOROURACIL; MITOMYCIN C; OXALIPLATIN;

ABDOMINAL SURGERY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CAUTERIZATION; CHEMOSURGERY; CHOLECYSTECTOMY; COLON RESECTION; COLORECTAL CANCER; CYTOREDUCTIVE SURGERY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; EARLY POSTOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; HEMICOLECTOMY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; HYSTERECTOMY; LAPAROTOMY; OCCUPATIONAL EXPOSURE; OMENTECTOMY; PERITONECTOMY; PERITONEUM PSEUDOMYXOMA; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTOSIGMOIDECTOMY; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; SIGMOIDECTOMY; SPLENECTOMY; SURGICAL APPROACH;

EID: 84857148493     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2012.640825     Document Type: Review

References (55)

1. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465-72. (Pubitemid 36791900)
2. Miner TJ, Brennan MF, Jaques DP. A prospective, symptom related, outcomes analysis of 1022 palliative procedures for advanced cancer. Ann Surg 2004;240:719-26.
3. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [see comment]. J Natl Canc Inst 2000; 92:205-16.
4. Pelz J, Chua T, Esquivel J, Stojadinovic A, Doerfer J, Morris D, et al. Evaluation of best supportive care and systemic chemotherapy as treatment stratified according to the retrospective Peritoneal Surface Disease Severity Score (PSDSS) for peritoneal carcinomatosis of colorectal origin. BMC Cancer 2010;10:689.
5. Kohne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, et al. Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13:308-17. (Pubitemid 34704985)
6. Spratt JS, Adcock RA, Muskovin M, Sherrill W, McKeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res 1980;40:256-60. (Pubitemid 10140145)
7. Gilly FN, Carry PY, Sayag AC, Braillon GB, Volloch AA, Panteix GG, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia with mitomycin C. Initial experience. Ann Chir 1990;44:545-51. (Pubitemid 20323357)
8. Sugarbaker PH, Gianola FJ, Speyer JC, Wesley R, Barofsky I, Meyers CE. Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer. Surgery 1985; 98:414-22. (Pubitemid 16143766)
9. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221:29-42.
10. Sugarbaker PH, Graves T, De Bruijn EA, Cunliffe WJ, Mullins RE, Hull WE, et al. Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies. Cancer Res 1990;50:5790-4. (Pubitemid 20331378)
11. Jacquet P, Averbach A, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: pharmacokinetic studies. Oncology 1998;55:130-8. (Pubitemid 28052257)
12. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002;89: 1545-50. (Pubitemid 35404323)
13. Kurita N, Shimada M, Utsunomiya T, Iwata T, Nishioka M, Yoshikawa K, et al. Predictive factors of peritoneal metastasis in gastric cancer. Hepatogastroenterology 2010;57:980-3.
14. Yang S-H, Lin J-K, LaiC-R,Chen C-C, LiAF-Y, LiangW-Y, et al. Risk factors for peritoneal dissemination of colorectal cancer. J Surg Oncol 2004;87:167-73. (Pubitemid 39167383)
15. Pollheimer MJ, Kornprat P, Pollheimer VS, Lindtner RA, Schlemmer A, Rehak P, et al. Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int J Colorectal Dis 2010;25:187-96.
16. Nozoe T, Anai H, Nasu S, Sugimachi K. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000;75:103-7.
17. Chen JS, Hsieh PS, Chiang JM, Yeh CY, Tsai WS, Tang R, et al. Clinical outcome of signet ring cell carcinoma and mucinous adenocarcinoma of the colon. Chang Gung Med J 2010;33:51-7.
18. Hidaka S, Tanaka K, Takeshita H, Sumida Y, Fukuoka H, Abo T, et al. Clinicopathology and prognosis of mucinous gastric carcinoma. Hepatogastroenterology 2008;55:791-4. (Pubitemid 351741550)
19. Pande R, Sunga A, Levea C, Wilding GE, Bshara W, Reid M, et al. Significance of signet-ring cells in patients with colorectal cancer. Dis Colon Rectum 2008;51:50-5.
20. Korenaga D, Ueo H, Mochida K, Kusumoto T, Baba H, Tamura S, et al. Prognostic factors in Japanese patients with colorectal cancer: the significance of large bowel obstruction- univariate and multivariate analyses. J Surg Oncol 1991;47: 188-92.
21. Cheynel N, Cortet M, Lepage C, Ortega-Debalon P, Faivre J, Bouvier AM. Incidence, patterns of failure, and prognosis of perforated colorectal cancers in a well-defined population. Dis Colon Rectum 2009;52:406-11.
22. Baskaranathan S, Philips J, McCredden P, Solomon MJ. Free colorectal cancer cells on the peritoneal surface: correlation with pathologic variables and survival. Dis Colon Rectum 2004;47:2076-9. (Pubitemid 40179068)
23. Wang J, Shi YK, Wu LY, Wang JW, Yang S, Yang JL, et al. Prognostic factors for ovarian metastases from primary gastric cancer. Int J Gynecol Cancer 2008;18:825-32. (Pubitemid 352020167)
24. Fujiwara A, Noura S, Ohue M, Shingai T, Yamada T, Miyashiro I, et al. Significance of the resection of ovarian metastasis from colorectal cancers. J Surg Oncol 2010;102: 582-7.
25. Sugarbaker PH, Averbach AM. Krukenberg syndrome as a natural manifestation of tumor cell entrapment. Cancer Treat Res 1996;82:163-91.
26. Ito H, Perez A, Brooks DC, Osteen RT, Zinner MJ, Moore FD, et al. Surgical treatment of small bowel cancer: a 20-year single institution experience. J Gastrointest Surg 2003;7:925-30. (Pubitemid 37338560)
27. Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology 2007;54: 129-34. (Pubitemid 46511661)
28. Wu CW, Lo SS, Shen KH, Hsieh MC, Chen JH, Chiang JH, et al. Incidence and factors associated with recurrence patterns after intended curative surgery for gastric cancer. World J Surg 2003;27:153-8.
29. Koppe MJ, Boerman OC, Oyen WJ, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006;243:212-22. (Pubitemid 43185440)
30. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996;82:359-74.
31. Carmignani CP, Sugarbaker TA, Bromley CM, Sugarbaker PH. Intraperitoneal cancer dissemination: mechanisms of the patterns of spread. Cancer Metastasis Rev 2003;22:465-72. (Pubitemid 36791900)
32. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221:29-42.
33. Z'graggen K, Birrer S, Maurer CA, Wehrli H, Klaiber C, Baer HU. Incidence of port site recurrence after laparoscopic cholecystectomy for preoperatively unsuspected gallbladder carcinoma. Surgery 1998;124:831-8. (Pubitemid 28520774)
34. Yan TD, Links M, Fransi S, Jacques T, Black D, Saunders V, et al. Learning curve for cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal surface malignancy-a journey to becoming a Nationally Funded Peritonectomy Center. Ann Surg Oncol 2007;14: 2270-80. (Pubitemid 47174916)
35. Chua TC, Liauw W, Saxena A, Al-Mohaimeed K, Fransi S, Zhao J, et al. Evolution of locoregional treatment for peritoneal carcinomatosis: single-center experience of 308 procedures of cytoreductive surgery and perioperative intraperitoneal chemotherapy. Am J Surg 2011;201:149-56.
36. Chua TC, Yan TD, Saxena A, Morris DL. Should the treatment of peritoneal carcinomatosis by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy still be regarded as a highly morbid procedure?: a systematic review of morbidity and mortality. Ann Surg 2009;249:900-7.
37. Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductivesurgery combine with perioperative intraperitoneal chemotherapy. Cancer 2011;116:5608-18.
38. Sugarbaker PH. Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach. Expert Opin Pharmacother 2009;10: 1965-77.
39. Guerbet M, Goullé JP, Lubrano J. Evaluation of the risk of contamination of surgical personnel by vaporization of oxaliplatin during the intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Eur J Surg Oncol 2007;33:623-6. (Pubitemid 46746543)
40. Schmid K, Boettcher MI, Pelz JO, Meyer T, Korinth G, Angerer J, et al. Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin C. Eur J Surg Oncol 2006;32:1222-5. (Pubitemid 44774394)
41. Näslund Andréasson S, Anundi H, Thorén SB, Ehrsson H, Mahteme H. Is platinum present in blood and urine from treatment givers during hyperthermic intraperitoneal chemotherapy? J Oncol 2010;64:971-9.
42. Chua TC, Liauw W, Zhao J, Morris DL. Analysis of perioperative intraperitoneal chemotherapy regimen in determining survival after cytoreduction for appendiceal and colorectal peritoneal carcinomatosis. J Surg Oncol 2011; in press.
43. McArdle CS, Kerr DJ, O'Gorman P, Wotherspoon HA, Warren H, Watson D, et al. Pharmacokinetic study of 5-fluorouracil in a novel dialysate solution: a long-term intraperitoneal treatment approach for advanced colorectal carcinoma. Br J Cancer 1994;70:762-6. (Pubitemid 24305618)
44. Kerr DJ, Young AM, Neoptolemos JP, Sherman M, Van- Geene P, Stanley A, et al. Prolonged intraperitoneal infusion of 5-fluorouracil using a novel carrier solution. Br J Cancer 1996;74:2032-5. (Pubitemid 27007154)
45. Wenzel LB, Huang HQ, Armstrong DK, Walker JL, Cella D, Group GO. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:437-43. (Pubitemid 350002993)
46. Welch JP, Doanldson GA. The clinical correlation of an autopsy study of recurrent colorectal cancer. Ann Surg 1979;189:496-502. (Pubitemid 9172343)
47. Gilbert JM. Distribution of metastases at necropsy in colorectal cancer. Clin Exp Metastasis 1983;1:97-101. (Pubitemid 13029502)
48. Weiss L, Grundmann E, Torhorst J, Hartveit F, Moberg I, Eder M, et al. Haematogenous metastastic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986;150:195-203. (Pubitemid 17181753)
49. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737-43. (Pubitemid 46606227)
50. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22:3284-92. (Pubitemid 41103684)
51. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006;24:4011-19. (Pubitemid 46630752)
52. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe J-M, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009;27: 681-5.
53. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, et al. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a Multicenter Study. Ann Surg Oncol 2011; Epub ahead of print.
54. Elias D, Bonnay M, Puizillou JM, Antoun S, Demirdjian S, El Otmany A, et al. Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution. Ann Oncol 2002;13:267-72. (Pubitemid 34704979)
55. Elias D, Goere D, Di Pietrantonio D, Boige V, Malka D, Kohneh-Shahri N, et al. Results of systematic secondlook surgery in patients at high risk of developing colorectal peritoneal carcinomatosis. Ann Surg 2008;247: 445-50.